Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally activelipoxygenaseinhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes^[1][2][3].

Masoprocol (30 μM; 90 min) shows high basal and insulin-stimulated glucose clearance in adipocytes^[2].

Masoprocol (150 mg/kg; i.g.; twice a day for 12 days) shows antihyperglycemic activity with the decreases in glucose concentration in plasma in male C57BL/ks-db/db mice^[1]. Masoprocol （0.83 mmol/kg; twice a day for 4 days）shows low glucose concentrations an average of 35% and low triglyceride concentrations of 80% compared with the vehicle at a rat model of type II diabetes^[2]. Masoprocol (40-80 mg/kg; p.o.; twice daily for 8 days) significantly reduces hepatic triglyceride (TG) secretion (P<.01) and liver TG content in a nondiabetic rat model with dietary-induced hypertriglyceridemia(HTG)^[3].

302.36

C₁₈H₂₂O₄

27686-84-6

• Phenols
• Polyphenols

• Plants
• other families

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.